Oct 12 close
Septerna trades at $37.56, down 2.1% on the day, sitting between its 50-day average of $39.45 and 200-day average of $31.15. Over the past month the stock is down 2.5%, though it remains up 8.7% over three months and 60.9% over six months, with a 52-week range of $17.55 to $51.10. The GekkoIndex reads 60.1, placing Septerna in the Accumulation zone after slipping 2.3 points over the past five sessions. Price sits 17.1% below Gekko Fair Value of $45.32.
Septerna's next earnings report is due 9 November 2026, 27 days out and within a typical 20-trading-day holding period; the prior report on 10 August 2026 showed an EPS of -$0.29 against a -$0.43 estimate, with a 23% reaction, and beats in 3 of 8 recent quarters, averaging a 6.3% absolute move. Insider activity in the past 90 days shows 0 purchases and 1 sale, with one trailblazer holder identified and no billionaire holders. Consensus among 9 covering analysts is unanimous Buy, with a consensus target of $54.22, implying 44.4% upside from current levels.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Septerna scores 2 supportive, 1 mixed and 2 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive1 mixed2 headwinds
Averages disagree
Close $37.56 sits between the 50-day ($39.45) and 200-day ($31.15) averages, or the averages disagree.
See the chart60.1, Accumulation
Reading 60.1 is in the Accumulation zone.
See the GekkoIndex17.1% below
Price is 17.1% below Gekko Fair Value (more than 5% below).
See fair valueLeans bearish
Last 90 days: insiders 0 open-market purchases / 1 sale.
See smart moneyReports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
Septerna closed at $37.56 on Oct 12, 2026, +62.3% over the past year, inside a 52-week range of $17.55 to $51.10.
Use the left and right arrow keys to read daily values.
Put SEPN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Septerna is a clinical-stage biotechnology company that works on oral small molecule medicines targeting G protein-coupled receptors. Its research spans endocrinology, immunology and inflammation, and metabolic disease, with additional interest in neurology, women's health, cardiovascular disease, and respiratory conditions. The company is perhaps best recognized for its pipeline of GPCR-focused programs, including an oral agonist approach aimed at hypoparathyroidism, a compound called SEP-631 being studied for chronic spontaneous urticaria and related mast cell conditions, and a program targeting Graves' disease and thyroid eye disease.
Beyond its own pipeline, Septerna has entered into a global collaboration and licensing arrangement with Novo Nordisk, under which the two work together to discover, develop, and bring to market oral small molecule treatments aimed at specified targets linked to metabolic disease.
The company was originally established under the name GPCR NewCo, Inc. before adopting its current name in June 2021, and it was incorporated in 2019. It is headquartered in South San Francisco, California, and its shares trade on the NASDAQ under the ticker SEPN.
Septerna’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.1, in the Accumulation zone, down 2.3 points over five sessions.
Down 2.3 points over five sessions.
Reading for Oct 12, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 20 | −12.7% | −20.9% | ||
| Accumulation (current zone) | 144 | +1.8% | +1.7% | ||
| Neutral | 278 | +2.0% | +9.7% | ||
| Distribution | 42 | +1.5% | +6.4% | ||
| Selling | 1 | Too few readings yet | |||
Average SEPN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
Septerna trades 17.1% below Gekko Fair Value of $45.32, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Septerna shares are worth, recalculated every trading day.
$45.32
Gekko Fair Value, Oct 10, 2026
17.1% Undervalued
At the end of Aug 2026 the price was 21.1% below the estimate.
No open-market insider purchases were filed for Septerna, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
1 sale worth $7.39M
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 14 | Third Rock Ventures V, L.P. / Third Rock Ventures GP V, LP / TRV GP V, LLC / Third Rock Ventures VI, L.P. / Third Rock Ventures GP VI, L.P. / TRV GP VI, LLC 10% Owner | Sale | $7.39M |
From Form 4 filings, dated to when each was filed.
No trades in SEPN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Septerna has been buying back its own shares.
From company filings.
1of the funds Gekko tracks holds SEPN.
Septerna reports on Nov 9, 2026 (28 days away), and beat the EPS estimate in 3 of its last 8 reports.
Nov 9, 2026
28 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.29 est −$0.43 | $26.75M est $19.22M | +23.0% |
| May 12, 2026 | −$0.19 est −$0.44 | $26.52M est $16.98M | +5.0% |
| Mar 9, 2026 | −$0.24 est −$0.72 | $24.12M est $18.20M | −2.6% |
| Nov 10, 2025 | −$0.09 est $0.19 | $21.50M est $17.27M | +3.9% |
| Aug 11, 2025 | −$0.56 est −$0.05 | $119K est $5.00M | −4.2% |
| May 15, 2025 | −$0.49 est −$0.38 | $219K est $30.00M | −3.1% |
| Nov 21, 2024 | −$8.40 est −$0.83 | $176K | −2.2% |
| Aug 28, 2024 | −$12.76 est $0.00 | — | — |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Septerna is $54.22, +44.4% from the last close, from 9 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 9 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | Wells Fargo | $50 | +33.1% |
| Aug 19 | J.P. Morgan | $48 | +27.8% |
| Aug 16 | Stifel Nicolaus | $46 | +22.5% |
| Aug 13 | Truist Financial | $59 | +57.1% |
| Aug 12 | Wells Fargo | $50 | +33.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Septerna’s market cap is $1.69B and revenue of $98.88M over the last twelve months.
Septerna’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Septerna’s market cap is $1.69B at the Oct 12, 2026 close of $37.56, with 46.68M shares outstanding.
The consensus analyst 12-month price target for Septerna is $54.22, +44.4% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Septerna is undervalued: the Oct 12, 2026 close of $37.56 is 17.1% below Gekko Fair Value of $45.32. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Septerna is expected to report on Nov 9, 2026 (28 days away). Analysts expect earnings of −$0.41 per share on revenue of $20.78M. Septerna beat the earnings estimate in 3 of its last 8 reports, moving 6.3% on average across the report.
Septerna’s 52-week high is $51.10 and its 52-week low is $17.55; it closed at $37.56 on Oct 12, 2026, +62.3% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 1 as mixed (trend) and 2 as headwinds (smart money and earnings risk). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.